These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 12233226)

  • 1. [Clinical study of the month. The LIPS study: fluvastatin for prevention of cardiac events following percutaneous coronary angioplasty].
    Scheen AJ
    Rev Med Liege; 2002 Jul; 57(7):479-82. PubMed ID: 12233226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial effects of fluvastatin following percutaneous coronary intervention in patients with unstable and stable angina: results from the Lescol intervention prevention study (LIPS).
    Lee CH; de Feyter P; Serruys PW; Saia F; Lemos PA; Goedhart D; Soares PR; Umans VA; Ciccone M; Cortellaro M
    Heart; 2004 Oct; 90(10):1156-61. PubMed ID: 15367512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention--a Lescol Intervention Prevention Study (LIPS) substudy.
    Arampatzis CA; Goedhart D; Serruys PW; Saia F; Lemos PA; de Feyter P;
    Am Heart J; 2005 Feb; 149(2):329-35. PubMed ID: 15846273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective analysis of the effect of noncompliance on time to first major adverse cardiac event in LIPS.
    Lesaffre E; Kocmanová D; Lemos PA; Disco CM; Serruys PW
    Clin Ther; 2003 Sep; 25(9):2431-47. PubMed ID: 14604742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial.
    Serruys PW; de Feyter P; Macaya C; Kokott N; Puel J; Vrolix M; Branzi A; Bertolami MC; Jackson G; Strauss B; Meier B;
    JAMA; 2002 Jun; 287(24):3215-22. PubMed ID: 12076217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of fluvastatin on long-term outcome after coronary revascularization with stent implantation.
    Saia F; de Feyter P; Serruys PW; Lemos PA; Arampatzis CA; Hendrickx GR; Delarche N; Goedhart D; Lesaffre E; Branzi A;
    Am J Cardiol; 2004 Jan; 93(1):92-5. PubMed ID: 14697476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study.
    Norby GE; Holme I; Fellström B; Jardine A; Cole E; Abedini S; Holdaas H;
    Arthritis Rheum; 2009 Apr; 60(4):1060-4. PubMed ID: 19333947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluvastatin.
    Lawrence JM; Reckless JP
    Expert Opin Pharmacother; 2002 Nov; 3(11):1631-41. PubMed ID: 12437496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy).
    Lemos PA; Serruys PW; de Feyter P; Mercado NF; Goedhart D; Saia F; Arampatzis CA; Soares PR; Ciccone M; Arquati M; Cortellaro M; Rutsch W; Legrand V
    Am J Cardiol; 2005 Feb; 95(4):445-51. PubMed ID: 15695126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An economic evaluation of fluvastatin used for the prevention of cardiac events following successful first percutaneous coronary intervention in the UK.
    Scuffham PA; Chaplin S
    Pharmacoeconomics; 2004; 22(8):525-35. PubMed ID: 15217308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Lescol Intervention Prevention Study (LIPS): start all patients on statins early after PCI.
    Messerli AW; Aronow HD; Sprecher DL
    Cleve Clin J Med; 2003 Jun; 70(6):561-6. PubMed ID: 12828227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluvastatin reduces the 4-year cardiac risk in patients with multivessel disease.
    Lemos PA; de Feyter PJ; Serruys PW; Saia F; Arampatzis CA; Disco C; Mercado N; Mainar V; Morís C; van den Bos AA; Berghoefer G
    Int J Cardiol; 2005 Feb; 98(3):479-86. PubMed ID: 15708183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of fluvastatin in Hungary following successful percutaneous coronary intervention.
    Scuffham PA; Kósa J
    Cardiovasc Drugs Ther; 2006 Aug; 20(4):309-17. PubMed ID: 16779529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of plasma lipoprotein (a) on angiographic restenosis and coronary events in patients undergoing planned coronary balloon angioplasty. Ancillary analysis of the Fluvastatin Angioplasty Restenosis (FLARE) trial.
    Lloyd GW; Jackson G; Foley DP; Boersma E; Shepherd J; Serruys PW
    Atherosclerosis; 2001 Oct; 158(2):445-54. PubMed ID: 11583725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of fluvastatin following successful first percutaneous coronary intervention.
    Delea TE; Jacobson TA; Serruys PW; Edelsberg JS; Oster G
    Ann Pharmacother; 2005 Apr; 39(4):610-6. PubMed ID: 15741421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial.
    Holdaas H; Fellström B; Jardine AG; Holme I; Nyberg G; Fauchald P; Grönhagen-Riska C; Madsen S; Neumayer HH; Cole E; Maes B; Ambühl P; Olsson AG; Hartmann A; Solbu DO; Pedersen TR;
    Lancet; 2003 Jun; 361(9374):2024-31. PubMed ID: 12814712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cost-effectiveness analysis of fluvastatin in patients with diabetes after successful percutaneous coronary intervention.
    Scuffham PA; Chaplin S
    Clin Ther; 2005 Sep; 27(9):1467-77. PubMed ID: 16291420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of fluvastatin on plasma apolipoprotein-B-containing particles, including lipoprotein(a). European Fluvastatin Study Group.
    Dallongeville J; Fruchart JC; Pfister P; Bard JM
    J Intern Med Suppl; 1994; 736():95-101. PubMed ID: 7986315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.
    Plosker GL; Wagstaff AJ
    Drugs; 1996 Mar; 51(3):433-59. PubMed ID: 8882381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Fluvastatin in a comparative study. Are there substance-specific differences between various CSE-inhibitors?].
    Internist (Berl); 1999 Mar; 40(3 Suppl Gibt Es):1-4. PubMed ID: 10192028
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.